Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Short Interest Update

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) was the target of a large decrease in short interest in April. As of April 15th, there was short interest totalling 20,200 shares, a decrease of 8.6% from the March 31st total of 22,100 shares. Currently, 1.0% of the shares of the stock are sold short. Based on an average daily volume of 2,900 shares, the days-to-cover ratio is presently 7.0 days.

Cyclerion Therapeutics Price Performance

NASDAQ:CYCN traded up $0.15 during trading hours on Monday, hitting $3.08. The stock had a trading volume of 1,539 shares, compared to its average volume of 3,113. The firm has a market capitalization of $8.35 million, a price-to-earnings ratio of -0.56 and a beta of 1.84. Cyclerion Therapeutics has a one year low of $1.75 and a one year high of $6.75. The company has a 50 day simple moving average of $3.10 and a two-hundred day simple moving average of $3.05.

Institutional Trading of Cyclerion Therapeutics

An institutional investor recently raised its position in Cyclerion Therapeutics stock. Tyndall Capital Partners L P raised its stake in shares of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) by 11.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 164,429 shares of the company’s stock after purchasing an additional 16,717 shares during the quarter. Cyclerion Therapeutics accounts for about 100.0% of Tyndall Capital Partners L P’s holdings, making the stock its biggest holding. Tyndall Capital Partners L P owned approximately 6.71% of Cyclerion Therapeutics worth $551,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 75.62% of the stock is currently owned by hedge funds and other institutional investors.

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc, a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc for the treatment of rare kidney disease.